Treatment with IV donanemab in early-stage Alzheimer’s disease demonstrated sustained clinical benefits for up to 3 years, with early initiation responsible for better outcomes, data from a long-term ...

This approval brings the total to 4 of medications approved to treat fibromyalgia; in addition to cyclobenzaprine HCl ...

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients ...

Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly ...

Novo Nordisk’s stock popped Monday after it announced a cash discount for uninsured Ozempic users and gained FDA approval for ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...

Novo Nordisk stock gains as FDA expands Wegovy use, while Ozempic price cut aims to boost access and defend market share.

Price hikes are 'kick in the teeth' for patients who will either have to swallow 170 per cent price increase, or switch to ...

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...